{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-009852","form_type":"8-K","ticker":"ORKA","cik":"0000907654","company_name":"Oruka Therapeutics, Inc.","filed_at":"2024-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.239453+00:00","generated_at":"2026-06-06T12:28:37.198632+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ARCA biopharma posts 2023 net loss of $5.3M ($0.37/share); cash $37.4M","bullets":["Net loss improved to $5.3M from $9.9M in 2022; basic EPS loss $0.37 vs $0.69.","Cash and equivalents $37.4M at Dec 31, 2023, down from $42.4M; runway through mid-2025.","G&A expenses rose to $6.3M (2023) from $5.8M (2022) on higher professional and strategic review fees.","R&D expenses fell to $1.0M from $4.7M due to lower clinical costs and headcount reduction.","Strategic review ongoing with no defined timeline; potential merger, asset sale, or other alternatives."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-009852","json":"https://secwatch.observer/filing/0000950170-24-009852.json","markdown":"https://secwatch.observer/filing/0000950170-24-009852.md","text":"https://secwatch.observer/filing/0000950170-24-009852.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/907654/000095017024009852/0000950170-24-009852-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/907654/000095017024009852/abio-20240201.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T12:28:37.198632+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e8d5ac4b2a7759a6150937bc850cb21bef8d692a","claim":"Oruka Therapeutics, Inc. reported the year ended December 31, 2023 results: net income Net loss for the year ended December 31, 2023 was $5.3 million, or $0.37 per basic and diluted share, EPS $0.37 per basic and diluted share.","evidence_excerpt":"Net loss for the year ended December 31, 2023 was $5.3 million, or $0.37 per basic and diluted share, compared to $9.9 million, or $0.69 per basic and diluted share in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/907654/000095017024009852/0000950170-24-009852-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Net income","value":"Net loss for the year ended December 31, 2023 was $5.3 million, or $0.37 per basic and diluted share"},{"label":"EPS","value":"$0.37 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}